Sean, you, for Thank and us. you, thank joining everyone,
of that trend Association Diabetes strong, in X research This space. discussing time hours increase and at category results, non-insulin X begin overall CGM CGM as DexCom X,XXX studies, continues spectrum remained date the type at recent using we day as DexCom's evident let was for the DexCom and X to significant in range per evidence nearly of than customers real-world year. well QX multiple metabolic AXc reduction largest demand of state demonstrated showing Conference, a greater evidence across accelerate. me Before to awareness the the health featured American which value
the X the ensure are to tailored We course become are unique opportunity we future below second that generation saw of maximizing results leveraging the we the the trends evidence quarter needs market near-term systems increasingly emerge our several these of to each our into pathways expectations. drove CGM progress as of that customer.
Despite on fronts, our positive over
customers our expectations still through we've expansion, of our First, strong of absolute have we despite our new short realignment fall customer additions. share as force sales worked U.S. seen
levels. initial based mix. realized expectations rebate rebate X expected, relative on XXXX coverage customer eligibility eligibility we faster Second, greater stepped our U.S. channel drivers: and to than emerging revenue down per GX to expected has With faster and primary compared than
impact this we starts has to as rebate did the GX facilitate allow not mentioned of temporary pace While this us coverage these offset customer helped above, new believe from the starts, eligibility. enhanced
third expect color its We QX the shortly. quarter, on Jereme will and the eligibility dynamic reach the specific provide impact of rebate will in expectations peak this
saw care Beyond strong customer GX dynamic, our transitory impacted growth customer as dynamics. broadly. business X our channel pharmacy the eligibility type diabetes reach expand mix we U.S. has revenue into also per U.S. remained more by in we primary and
for However, us we've DME on those executed quarter trailed these our against business, DME and relationships. important remain plan. channel our has the not in well We to in growth this The distributors refocus our partnerships. need partners
lighter also performance quarter. was the Finally, our than expectations in international
as as delivered our some in regions. we these we and geographies in advances soften France, certain in category type strong the of X While such performance core saw penetration U.K. growth markets
We as diabetes. to drive runway see footprint, ahead continue people across our a with we international significant for access greater type X particularly
trends XX% organic these and guidance full for reflect we've XX% appropriately to to account growth. To assumption, year revenue lowered our base our
we for what this we We future have than and incredible unparalleled an experienced believe opportunity. expectations higher market We business have and an our incredible product quarter. pipeline
great myself my this forward. going team We more expect market, and team capable I of from also leading a but have more for
we are what we put our with position team with continue sales in to product starts position So and great our to momentum? portfolio, doing reestablish competitive field strengthen our enhance It clinicians. a which to
the includes of ] of it performance our our of DexCom U.S. even direct-to-Apple this requested expanded most our We with In app. system international smaller with launch our launching for several several Watch the included This for additions now users. has and a One+ quarter reaching cadence We've of logging the activity GX monthly among our GX, data markets updates, that expanded feature GX second software form medication in ingest the which better. making our the ability international we continuation international years. the GX, DexCom quarter, built on into to XX additional the been wind of second with [ markets factor connectivity and
the X. by more advanced GX the ID range the connectivity in We Insulet's support strengthened in a products XX%. most CGM of company's August expanded Tandem's stronger leadership than adhesive Omnipod upcoming GX summer launch into introduced the preparing and System DexCom's We've our Stelo. with of our Bluetooth customers we launch existing space Mobi to months, the the We've launches product history for expansive with integrations and our with while
are better We CGM to seeing the and non-insulin space the health demand for a that use created drive outcomes. system build consumer to and and we've engaging in people believe metabolic unique
delivery as to and product service build Our features, team digital our Amazon expect offer fulfillment, that opportunities be has Stelo including subscriptions that seamless XXXX. and more hard single great bring to customers, scalable model in for experience, be X% will a the both through revenue well contribution insightful $XXX. as e-commerce launch continue purchase to will below options full discounted monthly the we much of approximately stelo.com, support We'll a on for worked cost come. Stelo
to and of metabolic committed U.S. growth that maintain well are future. across approaches like greater very share us and retention our This personalized to reignite well updates management health these. will positions customer to high into what and We expanded our sales now our to is base. through feel the opportunity utilization force rates us enable capture We
practices. the into deep specialty dive technological diabetes leadership provides to ability the have that for DexCom We
a simplicity and ability and our busy We care platform have our practice. the to fits expanded primary how highlight also reach into of it
population soon of the and be the by Stelo advantage better the lowest and coverage the of cost out-of-pocket have to for OTC enhanced the We platform. insulin simplicity
to serve. working As market force, hard U.S. expanded significant we to to addressable systems future take also sales the steps our Stelo are we we broaden our in access ensure markets with into well and the our simplified
second and [ in worked published process can noninsulin go hypoglycemia. In into effect problematic quarter, ICD-XX October, documenting events diagnostic simplify with the the for May coverage. the our These CDC to CGM codes create users team ] of hypoglycemic in for that which were qualify codes, new
progressed in also in Our received customers diabetes international these as with on June. for and second insulin quarter we France began market coverage into serving X the expansion type people basal efforts
in in at market. taking that transitioned and our of the also crucial to of the Japan sales commercial to We control efforts look quarter forward direct outset
our as over With that, and Jereme. to move it are standards, up To look our better forward XXXX to not second quarter we and we I'll turn capitalizing forward. opportunity our summarize, performance outlook to on
